Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Valent/Evolva agree deal on bioactives

Sumitomo Chemical's US-based biopesticide and biorational products subsidiary, Valent BioSciences (VBC - Libertyville, Illinois), and Swiss sustainable technology company Evolva (Reinach) have agreed to co-develop and commercialise “a class of high-value active ingredients for use as next-generation agricultural bioactives”. The collaboration will start by developing yeast strains that make the desired ingredients. Evolva has the primary responsibility for this phase while VBC will be responsible for commercialisation. The companies will work together on scale-up and manufacturing. The first products from the collaboration are expected to be launched in 4-5 years. Total spending on the project during the next five years is estimated to reach CHF 12-14 million ($12.4-14.5 million). The companies have agreed to split the R&D costs and profits equally from active ingredient sales. "This collaboration aligns well with VBC’s growth strategy in the area of bioactives," says executive vice-president and COO Ted Melnik. Sumitomo Chemical is integrating VBC with its crop protection business in a two-phase process starting this month.


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts